Last updated: April 25, 2026
Clinical Trials Update, Market Analysis, and Projection: Omnipaque 300 (iohexol 300 mg iodine/mL)
What is Omnipaque 300 and where does it sit in the market?
Omnipaque 300 is an iodinated, non-ionic, monomeric contrast medium containing iohexol at 300 mg iodine/mL. It is used for computed tomography (CT) and other X-ray contrast imaging applications. As an established branded small-molecule product, it sits in a mature, heavily genericized radiology contrast market where competitive dynamics are driven by price, supply reliability, labeling breadth, and distribution access, not by clinical differentiation.
Regulatory positioning (examples):
- Omnipaque (iohexol) injection is an FDA-approved product used for contrast enhancement in CT and other imaging indications. FDA labeling provides the dosing and administration framework for iohexol products, including the 300 mg iodine/mL concentration variants. (FDA label for Omnipaque / iohexol products is referenced in the FDA database.) [1]
What is the current clinical-trials signal for Omnipaque 300?
Omnipaque 300 is a legacy imaging agent. In current public registries, the trial population typically shifts from branded concentration products to class-based or modality-based studies, often using generic or pooled “iohexol” wording rather than “Omnipaque 300” explicitly. That said, the practical clinical-trials footprint for Omnipaque 300 is best tracked via iohexol studies and radiology imaging protocols rather than brand-tagged trials.
Clinical-trials update (structure and how to interpret it):
- Registration naming is inconsistent. Public records often cite iohexol without specifying the branded concentration and packaging.
- Interventional signals are usually protocol- or comparator-driven, such as dosing strategy, injection rate, image quality, radiation dose optimization, and contrast reaction mitigation.
- Safety endpoints dominate: adverse reactions, hypersensitivity events, and hemodynamic tolerance in at-risk populations.
Bottom line for Omnipaque 300 specifically: there is no public indication of a large, brand-specific late-stage clinical program that would change product economics through new indication expansion. Market behavior in iodinated contrast is shaped primarily by regulatory maintenance, manufacturing scale, and contracting cycles rather than by novel RCT readouts for Omnipaque 300.
Public trial discovery anchor:
- Clinical trial listings for iohexol exist across CT imaging protocols and safety optimization categories in public registries (e.g., ClinicalTrials.gov). [2]
How does patent and exclusivity risk map to Omnipaque 300?
Omnipaque 300 is not an “option value” patent story in the way oncology assets are. The key economic reality is that iohexol is widely available. That means the branded value proposition is typically sustained through channel contracting, packaging/form-factor preferences, procurement relationships, and service-level commitments, rather than patent-driven market protection.
How to interpret exclusivity in practice:
- For legacy small molecules like iohexol, most brand protection tends to be exhausted or limited to labeling tweaks, manufacturing/process claims, or specific presentation formats.
- Pricing pressure from generics is a standard expectation in iodinated contrast.
Actionable consequence: forecast models should treat Omnipaque 300 as a mature revenue stream with competitive erosion risk rather than as a growth curve driven by patent life.
Market Analysis: What drives demand for Omnipaque 300?
What is the demand engine for iodinated contrast in CT?
CT utilization and imaging workflow standards drive demand:
- Rising CT volumes historically increase contrast usage.
- Clinical protocols (e.g., multiphase CT, oncology staging, vascular imaging) determine iodinated contrast consumption per patient.
- Economic constraints push lower acquisition cost where clinically acceptable, favoring generics.
Where do buyers concentrate purchasing power?
Buyer behavior clusters around:
- GPO contracts and hospital system formularies
- national and regional distribution agreements
- tender cycles for imaging supplies
- vendor-managed inventory programs and logistics SLAs
In practice, Omnipaque 300 pricing and volume outcomes often correlate with:
- hospital formulary tier placement,
- group purchasing dynamics,
- substitution policies (iohexol interchangeability),
- and stockout prevention performance.
Competitive landscape: How does Omnipaque 300 compete?
Who competes with Omnipaque 300?
The competitive set is dominated by:
- other iohexol brands and authorized generics, and
- other non-ionic iodinated contrast agents (class competition), depending on formulary decisions and imaging protocols.
Competitive substitution logic in hospitals:
- If two agents are therapeutically interchangeable under labeling and protocol, the contract price becomes the primary driver.
- For mature products, differentiators often reduce to:
- packaging and vial size availability,
- distribution reliability,
- and consistent pharmacovigilance performance.
Market projection: What is the outlook for Omnipaque 300 revenues?
How should Omnipaque 300 be projected in a mature branded setting?
For mature contrast agents, revenue forecasting usually decomposes into:
- Unit demand: patient imaging volumes times contrast dose distribution.
- Net price realization: contract price minus rebates, discounts, and distribution fees.
- Mix: vial size, concentration used, and protocol preference.
- Share shift: substitution between iohexol brands and among contrast classes.
Given iohexol market maturity, the projection should assume:
- growth is mostly tied to imaging volume, and
- net price declines with generic competition and contract pressure.
Scenario framework (base, down, up)
Because Omnipaque 300 is part of a class where pricing erosion is common, projections typically track a volume-plus margin compression pattern. A clean approach is to apply a scenario spread where:
- Base case: modest volume growth with continued net price pressure.
- Down case: faster share loss to authorized generics or stronger class competition at the contracting level.
- Up case: formulary persistence, stronger distribution placement, and stable net pricing.
Key modeling requirement: use contracted net price rather than list price and separate volume growth from share movement.
What would change the forecast materially?
Switch drivers to watch
- Contracting outcomes (GPO and IDN tender results) that re-rank product tiers.
- Regulatory label expansions or safety communications that shift procurement risk tolerance.
- Supply chain events that force temporary substitution and re-contracting.
- Clinical protocol changes affecting per-scan contrast dose volume.
Key Takeaways
- Omnipaque 300 is a mature branded iohexol (300 mg iodine/mL) iodinated contrast product with demand primarily driven by CT utilization and imaging protocols.
- Public clinical-trial activity for this space is typically iohexol-protocol based rather than brand-specific, and it does not currently indicate a large Omnipaque 300 late-stage development program that would change market trajectory. [2]
- The economic outlook should be modeled as volume growth offset by continued net price pressure due to generic and class competition typical for iodinated contrast agents.
- Material forecast movement is most likely to come from contracting and formulary share shifts, not from new clinical efficacy breakthroughs.
FAQs
1) Is Omnipaque 300 still under meaningful patent protection?
Omnipaque 300 is a legacy iohexol product; in practice, market economics reflect the maturity and widespread availability of iohexol, so branded value is sustained via contracting and channel relationships rather than patent exclusivity.
2) Do current clinical trials name “Omnipaque 300” specifically?
Clinical trial registries frequently use iohexol generic naming and protocol descriptors, so branded “Omnipaque 300” may not appear as the trial label even when the tested product class aligns with the brand.
3) What is the main clinical endpoint focus in ongoing iohexol studies?
Ongoing studies commonly emphasize safety (adverse reactions) and imaging performance (image quality, protocol optimization).
4) What drives hospital purchasing decisions for iodinated contrast?
Purchasing prioritizes contracted net price, formulary tier placement, and supply reliability, with clinical equivalence supporting substitution across iohexol options.
5) What is the most sensitive variable in revenue projections?
The most sensitive variable is net price realization after rebates and contract discounts, followed by share movement driven by tenders and switching behavior.
References
[1] U.S. Food and Drug Administration. Label information for Omnipaque (iohexol) injection. FDA database.
[2] U.S. National Library of Medicine. ClinicalTrials.gov: iohexol studies and CT imaging protocol trials. ClinicalTrials.gov database.
